conference Archives - MediaMedic

ESMO Expert Commentary | Professor Yao Zhu: Success or Failure Does Not Define a Hero, Numerous Prostate Cancer Studies Aid in Optimizing Patient Survival

By Mourabit Halima 2024.02.18

Prostate cancer is the leading male urological tumor in China and has become one of the fastest-growing male malignancies in the past decade. The recent ESMO conference unveiled several advancements in prostate cancer research, extending the survival prospects for patients. Although there were some negative results, the research still holds positive significance. "Oncology Frontier" has specially invited Professor Yao Zhu from Fudan University's affiliated Cancer Hospital to provide an in-depth interpretation of these research developments.

Doctor Philippa Easterbrook: WHO to Release New Hepatitis B Guidelines, Focusing on Expanding Treatment Eligibility and Simplifying Diagnosis and Treatment Pathways

By Xiaorong JI 2023.10.24

At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL 2023) and EASL Congress 2023, Doctor Philippa Easterbrook, Senior Scientist at the Global Hepatitis Programme of the Department of HIV at the World Health Organization (WHO) headquarters in Geneva, attended the WHO-ECDC Joint Forum. She discussed the new directions being drafted in WHO's updated Hepatitis B guidelines, focusing on expanding simplified treatment criteria, service delivery, and innovative diagnostics. Hepatology Digest had the privilege to interview Doctor Philippa Easterbrook about WHO's 2030 goals, the progress of the new Hepatitis B guidelines, essential information, and the global challenges and opportunities in addressing Hepatitis B prevention and control.

EASL Secretary-General: Doctor Thomas Berg Discusses Highlights of the Conference, NAFLD Renaming, and Future Directions for Fatty Liver and Hepatitis B Research

By Xiaorong JI 2023.10.24

The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023 have brought forth a splendid academic gathering for the global hepatology community. The Hepatology Digest reporting team had the privilege of interviewing Doctor Thomas Berg, EASL Secretary-General and Head of the Hepatology Department at Leipzig University Hospital. He shared with us the highlights of this conference, his perspective on significant research developments, thoughts on the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD), and insights into the future research directions for fatty liver and hepatitis B.

APASL President Doctor Shuichiro Shiina Invites You to Attend the 2024 the Asian Pacific Association for the Study of the Liver Conference in Kyoto, Japan

By Xiaorong JI 2023.10.24

At the 58th European Association for the Study of the Liver (EASL) Annual Meeting, also known as EASL 2023 Congress, Professor Shuichiro Shiina, the President of the Asian Pacific Association for the Study of the Liver (APASL) and a professor of gastroenterology at Juntendo University in Japan, was invited to attend the conference. He engaged in a stimulating roundtable discussion with hepatologists from various countries on the topic of "Hepatology and Hepatologists of the Future: Opportunities and Challenges." Hepatology Digest had the privilege of inviting Doctor Shuichiro Shiina to share his insights and experiences from his visit to EASL, as well as his expectations for the 2024 APASL Annual Meeting.

Interview with Dr. Girard Deciphers at ELCC 2023

By Peter W. PENG 2023.10.24

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.

2023 SGBCC Expert Voting: Radiotherapy

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, known as the "City of Music", from March 15th to 18th, 2023, local time. SGBCC brought together breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics regarding early-stage breast cancer treatment. This culminates in the St.Gallen early-stage breast cancer international expert consensus, which is updated every two years. On the last day of the conference, the expert voting was the highlight.

2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "World Music Capital," from March 15 to 18, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in early breast cancer diagnosis and treatment, forming an updated St.Gallen International Expert Consensus on Early Breast Cancer every two years. On the final day of the conference, expert voting took center stage. Oncology Frontier has compiled expert votes on two topics: adjuvant endocrine therapy and chemotherapy decisions for ER-positive breast cancer.

2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music", from March 15 to 18, 2023 local time. SGBCC gathered breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics related to early-stage breast cancer treatment. This forms the St.Gallen Early Breast Cancer International Expert Consensus, which is updated every two years. "Oncology Frontier" has compiled expert votes on topics related to early breast cancer's pathology, genes, DCIS, and male-related issues. Let's experience the St.Gallen atmosphere of early breast cancer treatment decision-making.

2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated, Bone Modifying Therapy, Molecular Diagnosis

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, known as the "Capital of World Music", from March 15th to 18th, 2023 local time. On the last day of the conference, the highlight was the expert voting session. Oncology Frontier has compiled expert voting on the treatment of HER2 positive breast cancer, BRCA Associated treatment, Bone Modifying Therapy , oligo-metastatic disease, and molecular diagnosis topics. Additionally, a selection of these topics was presented for readers to vote on, allowing them to immerse themselves in the St.Gallen atmosphere of early breast cancer treatment decision-making.

WCLC 2023 : Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

By Peng Geng 2023.10.23

On the final day of the 2023 World Conference on Lung Cancer (WCLC) , Oncology Frontier had the privilege of interviewing Dr. Wu Yilong from Guangdong Provincial People's Hospital, Dr. Cheng Ying from Jilin Cancer Hospital, and Dr. Han Baohui from Shanghai Chest Hospital. These three experts participated in a dialogue and discussion regarding hot topics at the conference and significant clinical research. Here present the highlights of their on-site discussions.